• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

小分子激活RNA（saRNAs）在人类癌症中的治疗潜力

Therapeutic Potential of Small Activating RNAs (saRNAs) in Human Cancers.

作者信息

Yoon Sorah, Rossi John J

机构信息

Department of Molecular and Cellular Biology, Beckman Research Institute of City of Hope, Duarte, California, United States.

Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, Duarte, California, United States.

出版信息

Curr Pharm Biotechnol. 2018;19(8):604-610. doi: 10.2174/1389201019666180528084059.

DOI:10.2174/1389201019666180528084059
PMID:29804529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6204660/
Abstract

BACKGROUND

RNA is increasingly recognized as a powerful molecule that can be used to control gene expression. Sophisticated, well-engineered RNA-based regulators are being developed as oligotherapeutics.

METHODS

In particular, small activating RNAs (saRNAs) are promising therapeutic options for targeting human diseases. Numerous saRNAs targeting multiple cancers have been developed in preclinical models. One saRNA targeting C/EBPα is currently undergoing clinical trials in liver cancer.

RESULTS AND CONCLUSION

In this review, we describe the current working model of the intracellular mechanism of saRNA, discuss the recent progress of saRNA therapeutics in preclinical and clinical trials, and current advances in targeted delivery using aptamers in detail.

摘要

背景

RNA越来越被认为是一种可用于控制基因表达的强大分子。复杂的、精心设计的基于RNA的调节剂正在被开发为寡核苷酸疗法。

方法

特别是，小激活RNA（saRNAs）是针对人类疾病的有前景的治疗选择。在临床前模型中已经开发了许多针对多种癌症的saRNAs。一种靶向C/EBPα的saRNA目前正在肝癌中进行临床试验。

结果与结论

在本综述中，我们描述了saRNA细胞内机制的当前工作模型，详细讨论了saRNA疗法在临床前和临床试验中的最新进展，以及使用适体进行靶向递送的当前进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22fa/6204660/3748755de311/CPB-19-604_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22fa/6204660/af9699f20d4d/CPB-19-604_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22fa/6204660/1b77462a37f7/CPB-19-604_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22fa/6204660/3748755de311/CPB-19-604_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22fa/6204660/af9699f20d4d/CPB-19-604_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22fa/6204660/1b77462a37f7/CPB-19-604_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22fa/6204660/3748755de311/CPB-19-604_F3.jpg

相似文献

1
Therapeutic Potential of Small Activating RNAs (saRNAs) in Human Cancers.小分子激活RNA（saRNAs）在人类癌症中的治疗潜力
Curr Pharm Biotechnol. 2018;19(8):604-610. doi: 10.2174/1389201019666180528084059.
2
Current Advances in Small Activating RNAs for Gene Therapy: Principles, Applications and Challenges.当前小激活 RNA 在基因治疗中的进展：原理、应用和挑战。
Curr Gene Ther. 2018;18(3):134-142. doi: 10.2174/1566523218666180619155018.
3
RNA Therapeutics for Treatment of Cardiovascular Diseases: Promises and Challenges.用于治疗心血管疾病的RNA疗法：前景与挑战
Circ Res. 2016 Sep 16;119(7):794-7. doi: 10.1161/CIRCRESAHA.116.308730.
4
Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma.小激活 RNA 激活肝癌中 C/EBPα 的机制。
Oncogene. 2019 May;38(18):3446-3457. doi: 10.1038/s41388-018-0665-6. Epub 2019 Jan 14.
5
Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.MTL-CEBPA的研发：用于肝细胞癌的小激活RNA药物
Curr Pharm Biotechnol. 2018;19(8):611-621. doi: 10.2174/1389201019666180611093428.
6
Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy.癌基因依赖性和基于靶向 RNAi 的抗癌治疗的潜力。
Biochem J. 2014 Jul 1;461(1):1-13. doi: 10.1042/BJ20140173.
7
Therapeutic potential of RNAi in metabolic diseases.RNA干扰在代谢性疾病中的治疗潜力。
Biotechniques. 2006 Apr;Suppl:31-6. doi: 10.2144/000112163.
8
Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs.进行干预：将小分子干扰RNA用作小分子药物的前景与障碍
Annu Rev Biomed Eng. 2006;8:377-402. doi: 10.1146/annurev.bioeng.8.061505.095848.
9
Small interfering RNA-based molecular therapy of cancers.基于小干扰RNA的癌症分子疗法。
Chin J Cancer. 2013 Sep;32(9):488-93. doi: 10.5732/cjc.012.10280. Epub 2013 Jan 18.
10
The Therapeutic Potential of Small Activating RNAs for Colorectal Carcinoma.小激活 RNA 在结直肠癌治疗中的潜力。
Curr Gene Ther. 2019;19(3):140-146. doi: 10.2174/1566523219666190708111404.

引用本文的文献

1
Exploring RNA therapeutics for urea cycle disorders.探索用于尿素循环障碍的 RNA 疗法。
J Inherit Metab Dis. 2024 Nov;47(6):1269-1277. doi: 10.1002/jimd.12807. Epub 2024 Oct 24.
2
Assembling the RNA therapeutics toolbox.组装RNA治疗工具箱。
Med Rev (2021). 2024 Mar 20;4(2):110-128. doi: 10.1515/mr-2023-0062. eCollection 2024 Apr.
3
Recent insights into the functions and mechanisms of antisense RNA: emerging applications in cancer therapy and precision medicine.反义RNA的功能与机制的最新见解：在癌症治疗和精准医学中的新兴应用

本文引用的文献

1
Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.使用 saRNA 激活 CEBPA 基因：用于肝癌的首个人体 saRNA 药物候选物的临床前研究。
Oncogene. 2018 Jun;37(24):3216-3228. doi: 10.1038/s41388-018-0126-2. Epub 2018 Mar 7.
2
Small activating RNA induced expression of VHL gene in renal cell carcinoma.小激活 RNA 诱导肾细胞癌中 VHL 基因的表达。
Int J Biochem Cell Biol. 2018 Apr;97:36-42. doi: 10.1016/j.biocel.2018.02.002. Epub 2018 Feb 6.
3
Activation of KLF4 expression by small activating RNA promotes migration and invasion in colorectal epithelial cells.
Front Chem. 2024 Jan 10;11:1335330. doi: 10.3389/fchem.2023.1335330. eCollection 2023.
4
Engineered exosomes as drug and RNA co-delivery system: new hope for enhanced therapeutics?工程外泌体作为药物和RNA共递送系统：增强治疗效果的新希望？
Front Bioeng Biotechnol. 2023 Sep 26;11:1254356. doi: 10.3389/fbioe.2023.1254356. eCollection 2023.
5
LINC01393, a Novel Long Non-Coding RNA, Promotes the Cell Proliferation, Migration and Invasion through MiR-128-3p/NUSAP1 Axis in Glioblastoma.LINC01393，一种新型长链非编码 RNA，通过 miR-128-3p/NUSAP1 轴促进脑胶质母细胞瘤的细胞增殖、迁移和侵袭。
Int J Mol Sci. 2023 Mar 20;24(6):5878. doi: 10.3390/ijms24065878.
6
Modulating epigenetic modifications for cancer therapy (Review).调控表观遗传修饰治疗癌症（综述）。
Oncol Rep. 2023 Mar;49(3). doi: 10.3892/or.2023.8496. Epub 2023 Feb 17.
7
Small Activating RNA Modulation of the G Protein-Coupled Receptor for Cancer Treatment.小分子激活 RNA 调节 G 蛋白偶联受体治疗癌症。
Adv Sci (Weinh). 2022 Sep;9(26):e2200562. doi: 10.1002/advs.202200562. Epub 2022 Jun 16.
8
The Progress and Promise of RNA Medicine─An Arsenal of Targeted Treatments.RNA 医学的进展与前景——靶向治疗的武器库。
J Med Chem. 2022 May 26;65(10):6975-7015. doi: 10.1021/acs.jmedchem.2c00024. Epub 2022 May 9.
9
Innovative developments and emerging technologies in RNA therapeutics.RNA 治疗学的创新发展与新兴技术。
RNA Biol. 2022;19(1):313-332. doi: 10.1080/15476286.2022.2027150. Epub 2021 Dec 31.
10
Regulatory noncoding RNAs: potential biomarkers and therapeutic targets in acute myeloid leukemia.调控性非编码RNA：急性髓系白血病中的潜在生物标志物和治疗靶点
Am J Blood Res. 2021 Oct 15;11(5):504-519. eCollection 2021.
小激活 RNA 激活 KLF4 表达促进结直肠上皮细胞的迁移和侵袭。
Cell Biol Int. 2018 Apr;42(4):495-503. doi: 10.1002/cbin.10926. Epub 2018 Jan 22.
4
Enhanced wild-type p53 expression by small activating RNA dsP53-285 induces cell cycle arrest and apoptosis in pheochromocytoma cell line PC12.小激活 RNA dsP53-285 增强野生型 p53 的表达诱导嗜铬细胞瘤细胞系 PC12 细胞周期停滞和凋亡。
Oncol Rep. 2017 Nov;38(5):3160-3166. doi: 10.3892/or.2017.5993. Epub 2017 Sep 25.
5
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.靶向 CEBPA 的小激活 RNA 的开发和作用机制，一种用于肝癌临床试验的新型治疗方法。
Mol Ther. 2017 Dec 6;25(12):2705-2714. doi: 10.1016/j.ymthe.2017.07.018. Epub 2017 Aug 4.
6
SaRNA-mediated activation of TRPV5 reduces renal calcium oxalate deposition in rat via decreasing urinary calcium excretion.SaRNA 介导的 TRPV5 激活通过减少尿钙排泄降低大鼠肾脏草酸钙沉积。
Urolithiasis. 2018 Jun;46(3):271-278. doi: 10.1007/s00240-017-1004-z. Epub 2017 Aug 3.
7
Emerging cancer-specific therapeutic aptamers.新兴的癌症特异性治疗性适配体。
Curr Opin Oncol. 2017 Sep;29(5):366-374. doi: 10.1097/CCO.0000000000000389.
8
Aptamers as targeted therapeutics: current potential and challenges.适配体作为靶向治疗药物：当前的潜力与挑战
Nat Rev Drug Discov. 2017 Mar;16(3):181-202. doi: 10.1038/nrd.2016.199. Epub 2016 Nov 3.
9
Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy.小激活RNA上调钠碘同向转运体表达：在肝细胞癌内放射治疗中有广阔前景。
Cancer Gene Ther. 2016 Oct;23(10):333-340. doi: 10.1038/cgt.2016.36. Epub 2016 Sep 9.
10
Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis.通过靶向启动子的小激活RNA方法增强DPYSL3基因表达可抑制癌细胞的运动性和转移。
Oncotarget. 2016 Apr 19;7(16):22893-910. doi: 10.18632/oncotarget.8290.